Pharming Group publishes Q3 2026 results call transcript
PHAR•Pharming Group reported third-quarter revenue up 21% to USD 117.6 million and narrowed full-year revenue guidance to USD 380 million–390 million. It lowered operating expense guidance to USD 310 million–315 million.
1. Quarterly results and guidance
Pharming Group’s October 27 results call featured interim co-CEOs Kenneth Lynard and Leverne Marsh and Chief Medical Officer Anurag Relan. Management narrowed full-year revenue guidance to USD 380 million–390 million and lowered operating expense guidance to USD 310 million–315 million.
2. RUCONEST and leniolisib
Quarterly revenue rose 21% to USD 117.6 million, supported by RUCONEST’s return to growth. Early inventory building contributed 9 percentage points of RUCONEST’s 14% growth and could affect fourth-quarter revenue. Leniolisib CVID trial results are expected in November and will inform a potential Phase III study following positive genetic immunodeficiency data.
